VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice

M.M. Santoro, D.D. Carlo, D. Armenia, M. Zaccarelli, C. Pinnetti, M. Colafigli, F. Prati, A. Boschi, A.M. Degli Antoni, F. Lagi, L. Sighinolfi, C. Gervasoni, M. Andreoni, A. Antinori, C. Mussini, C.F. Perno, V. Borghi, G. Sterrantino

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)249-257
Number of pages9
JournalAntiviral Therapy
Volume23
Issue number3
DOIs
Publication statusPublished - 2018

Keywords

  • antiretrovirus agent
  • atazanavir plus ritonavir
  • darunavir plus ritonavir
  • dolutegravir
  • efavirenz
  • elvitegravir
  • integrase inhibitor
  • lopinavir plus ritonavir
  • nevirapine
  • nonnucleoside reverse transcriptase inhibitor
  • proteinase inhibitor
  • raltegravir
  • RNA directed DNA polymerase inhibitor
  • adult
  • antiretroviral therapy
  • CD4+ T lymphocyte
  • clinical practice
  • Conference Paper
  • female
  • human
  • Human immunodeficiency virus 1 infection
  • immune reconstitution
  • major clinical study
  • male
  • observational study
  • prescription
  • priority journal
  • probability
  • retrospective study
  • survival analysis
  • virus load

Cite this

Santoro, M. M., Carlo, D. D., Armenia, D., Zaccarelli, M., Pinnetti, C., Colafigli, M., ... Sterrantino, G. (2018). VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antiviral Therapy, 23(3), 249-257. https://doi.org/10.3851/IMP3197

VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. / Santoro, M.M.; Carlo, D.D.; Armenia, D.; Zaccarelli, M.; Pinnetti, C.; Colafigli, M.; Prati, F.; Boschi, A.; Degli Antoni, A.M.; Lagi, F.; Sighinolfi, L.; Gervasoni, C.; Andreoni, M.; Antinori, A.; Mussini, C.; Perno, C.F.; Borghi, V.; Sterrantino, G.

In: Antiviral Therapy, Vol. 23, No. 3, 2018, p. 249-257.

Research output: Contribution to journalArticle

Santoro, MM, Carlo, DD, Armenia, D, Zaccarelli, M, Pinnetti, C, Colafigli, M, Prati, F, Boschi, A, Degli Antoni, AM, Lagi, F, Sighinolfi, L, Gervasoni, C, Andreoni, M, Antinori, A, Mussini, C, Perno, CF, Borghi, V & Sterrantino, G 2018, 'VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice', Antiviral Therapy, vol. 23, no. 3, pp. 249-257. https://doi.org/10.3851/IMP3197
Santoro, M.M. ; Carlo, D.D. ; Armenia, D. ; Zaccarelli, M. ; Pinnetti, C. ; Colafigli, M. ; Prati, F. ; Boschi, A. ; Degli Antoni, A.M. ; Lagi, F. ; Sighinolfi, L. ; Gervasoni, C. ; Andreoni, M. ; Antinori, A. ; Mussini, C. ; Perno, C.F. ; Borghi, V. ; Sterrantino, G. / VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. In: Antiviral Therapy. 2018 ; Vol. 23, No. 3. pp. 249-257.
@article{cbf8f182437c4521b8b5e163ad60d4d1,
title = "VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice",
keywords = "antiretrovirus agent, atazanavir plus ritonavir, darunavir plus ritonavir, dolutegravir, efavirenz, elvitegravir, integrase inhibitor, lopinavir plus ritonavir, nevirapine, nonnucleoside reverse transcriptase inhibitor, proteinase inhibitor, raltegravir, RNA directed DNA polymerase inhibitor, adult, antiretroviral therapy, CD4+ T lymphocyte, clinical practice, Conference Paper, female, human, Human immunodeficiency virus 1 infection, immune reconstitution, major clinical study, male, observational study, prescription, priority journal, probability, retrospective study, survival analysis, virus load",
author = "M.M. Santoro and D.D. Carlo and D. Armenia and M. Zaccarelli and C. Pinnetti and M. Colafigli and F. Prati and A. Boschi and {Degli Antoni}, A.M. and F. Lagi and L. Sighinolfi and C. Gervasoni and M. Andreoni and A. Antinori and C. Mussini and C.F. Perno and V. Borghi and G. Sterrantino",
note = "Export Date: 23 November 2018 CODEN: ANTHF Correspondence Address: Santoro, M.M.; Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’Italy; email: santormaria@gmail.com Chemicals/CAS: dolutegravir, 1051375-16-6, 1051375-19-9, 1172581-47-3; efavirenz, 154598-52-4; elvitegravir, 697761-98-1; nevirapine, 129618-40-2; proteinase inhibitor, 37205-61-1; raltegravir, 518048-05-0, 871038-72-1, 889131-29-7 Funding details: # 1 Funding text 1: We gratefully thank Andrea Biddittu (University of Rome 'Tor Vergata', Rome, Italy), Alberto Giannetti (National Institute for Infectious Diseases L Spallanzani [IRCCS], Rome, Italy), Massimiliano Bruni (Aviralia Foundation Onlus, Rome, Italy) and Marzia Romani (University of Rome 'Tor Vergata', Rome, Italy) for data management. The manuscript was in part presented at the 13th European Meeting on HIV and Hepatitis Treatment and Strategies and Antiviral Drug Resistance, 3–5  June 2015, Barcelona, Spain (Abstract # 1) and at the 14th European Meeting on HIV and Hepatitis Treatment and Strategies and Antiviral Drug Resistance, 25–27 May 2016, Rome, Italy (abstract P68). References: Saag, M.S., Holodniy, M., Kuritzkes, D.R., HIV viral load markers in clinical practice (1996) Nat Med, 2, pp. 625-629; Soc{\'i}as, M.E., Sued, O., Laufer, N., Acute retroviral syndrome and high pre-therapy viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters (2011) J Int AIDS Soc, 14, p. 40; Guiguet, M., Bou{\'e}, F., Cadranel, J., Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study (2009) Lancet Oncol, 10, pp. 1152-1159; Mellors, J.W., Mu{\~n}oz, A., Giorgi, J.V., Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection (1997) Ann Intern Med, 126, pp. 946-954; Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Declining morbidity and mortality among patients with advanced human immunodeficiency virus Infection (1998) N Engl J Med, 338, pp. 853-860; Egger, M., May, M., Ch{\^e}ne, G., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies (2002) Lancet, 360, pp. 119-129; Robbins, G.K., Daniels, B., Zheng, H., Chueh, H., Meigs, J.B., Freedberg, K.A., Predictors of antiretroviral treatment failure in an urban HIV clinic (2007) J Acquir Immune Defic Syndr, 44, pp. 30-37; Haubrich, R.H., Riddler, S.A., Ribaudo, H., Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection (2011) AIDS, 25, pp. 2269-2278; Cozzi-Lepri, A., Dunn, D., Pillay, D., Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy (2010) Clin Infect Dis, 50, pp. 1275-1285; Santoro, M.M., Armenia, D., Alteri, C., Impact of pre-therapy viral load on virological response to modern first-line HAART (2013) Antivir Ther, 18, pp. 867-876; (2015) Guidelines for The Clinical Management and Treatment of HIV Infected Adults in Europe, , http://www.eacsociety.org/files/guidelines_8.2-english.pdf, Version 8.0. Accessed 31 July 2017; G{\"u}nthard, H.F., Saag, M.S., Benson, C.A., Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel (2016) JAMA, 316, pp. 191-210; (2006) Guidelines for The Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, , https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents. Updated 14 July Accessed 26 April 2017; Armenia, D., Soulie, C., Di Carlo, D., A very low geno2pheno false positive rate is associated with poor VIRO-immunological response in drug-naive patients starting a first-line HAART (2014) PLoS One, 9, p. e105853; Di Biagio, A., Rusconi, S., Marzocchetti, A., The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy (2014) J Med Virol, 86, pp. 1648-1655; Hanf, K.M., Jovelin, T., Hall, N., Impact of baseline viral load, time to viral suppression, and drug class on virologic rebound (2015) 15th European AIDS Conference, , 21–24 October Barcelona, Spain. Abstract PS10/1; Daar, E.S., Tierney, C., Fischl, M.A., Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 (2011) Ann Intern Med, 154, pp. 445-456; Molina, J.M., Clotet, B., Van Lunzen, J., Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, Phase 3b study (2015) Lancet HIV, 2, pp. e127-e136; Smith, K.Y., Patel, P., Fine, D., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/ lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir for initial HIV treatment (2009) AIDS, 23, pp. 1547-1556; Soriano, V., Arast{\'e}h, K., Migrone, H., Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial (2011) Antivir Ther, 16, pp. 339-348; Patel, D.A., Snedecor, S.J., Tang, W.Y., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: A systematic review and network meta-analysis (2014) PLoS One, 9, p. e105653; Wang, X., Song, X., Tang, S., Rong, L., Dynamics of an HIV model with multiple infection stages and treatment with different drug classes (2016) Bull Math Biol, 78, pp. 322-349; Riddler, S.A., Haubrich, R., DiRienzo, A.G., Class-sparing regimens for initial treatment of HIV-1 infection (2008) N Engl J Med, 358, pp. 2095-2106; Ch{\'e}ret, A., Nembot, G., M{\'e}lard, A., Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): A randomised, open-label, Phase 3 trial (2015) Lancet Infect Dis, 15, pp. 387-396; Markowitz, M., Evering, T.H., Garmon, D., A randomized open-label study of 3- Versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals (2014) J Acquir Immune Defic Syndr, 66, pp. 140-147; Clotet, B., Feinberg, J., Van Lunzen, J., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label Phase 3b study (2014) Lancet, 383, pp. 2222-2231; Kelley, C.F., Kitchen, C.M., Hunt, P.W., Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment (2009) Clin Infect Dis, 48, pp. 787-794; Lok, J.J., Bosch, R.J., Benson, C.A., Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection (2010) AIDS, 24, pp. 1867-1876",
year = "2018",
doi = "10.3851/IMP3197",
language = "English",
volume = "23",
pages = "249--257",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "3",

}

TY - JOUR

T1 - VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice

AU - Santoro, M.M.

AU - Carlo, D.D.

AU - Armenia, D.

AU - Zaccarelli, M.

AU - Pinnetti, C.

AU - Colafigli, M.

AU - Prati, F.

AU - Boschi, A.

AU - Degli Antoni, A.M.

AU - Lagi, F.

AU - Sighinolfi, L.

AU - Gervasoni, C.

AU - Andreoni, M.

AU - Antinori, A.

AU - Mussini, C.

AU - Perno, C.F.

AU - Borghi, V.

AU - Sterrantino, G.

N1 - Export Date: 23 November 2018 CODEN: ANTHF Correspondence Address: Santoro, M.M.; Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’Italy; email: santormaria@gmail.com Chemicals/CAS: dolutegravir, 1051375-16-6, 1051375-19-9, 1172581-47-3; efavirenz, 154598-52-4; elvitegravir, 697761-98-1; nevirapine, 129618-40-2; proteinase inhibitor, 37205-61-1; raltegravir, 518048-05-0, 871038-72-1, 889131-29-7 Funding details: # 1 Funding text 1: We gratefully thank Andrea Biddittu (University of Rome 'Tor Vergata', Rome, Italy), Alberto Giannetti (National Institute for Infectious Diseases L Spallanzani [IRCCS], Rome, Italy), Massimiliano Bruni (Aviralia Foundation Onlus, Rome, Italy) and Marzia Romani (University of Rome 'Tor Vergata', Rome, Italy) for data management. The manuscript was in part presented at the 13th European Meeting on HIV and Hepatitis Treatment and Strategies and Antiviral Drug Resistance, 3–5  June 2015, Barcelona, Spain (Abstract # 1) and at the 14th European Meeting on HIV and Hepatitis Treatment and Strategies and Antiviral Drug Resistance, 25–27 May 2016, Rome, Italy (abstract P68). References: Saag, M.S., Holodniy, M., Kuritzkes, D.R., HIV viral load markers in clinical practice (1996) Nat Med, 2, pp. 625-629; Socías, M.E., Sued, O., Laufer, N., Acute retroviral syndrome and high pre-therapy viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters (2011) J Int AIDS Soc, 14, p. 40; Guiguet, M., Boué, F., Cadranel, J., Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study (2009) Lancet Oncol, 10, pp. 1152-1159; Mellors, J.W., Muñoz, A., Giorgi, J.V., Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection (1997) Ann Intern Med, 126, pp. 946-954; Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Declining morbidity and mortality among patients with advanced human immunodeficiency virus Infection (1998) N Engl J Med, 338, pp. 853-860; Egger, M., May, M., Chêne, G., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies (2002) Lancet, 360, pp. 119-129; Robbins, G.K., Daniels, B., Zheng, H., Chueh, H., Meigs, J.B., Freedberg, K.A., Predictors of antiretroviral treatment failure in an urban HIV clinic (2007) J Acquir Immune Defic Syndr, 44, pp. 30-37; Haubrich, R.H., Riddler, S.A., Ribaudo, H., Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection (2011) AIDS, 25, pp. 2269-2278; Cozzi-Lepri, A., Dunn, D., Pillay, D., Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy (2010) Clin Infect Dis, 50, pp. 1275-1285; Santoro, M.M., Armenia, D., Alteri, C., Impact of pre-therapy viral load on virological response to modern first-line HAART (2013) Antivir Ther, 18, pp. 867-876; (2015) Guidelines for The Clinical Management and Treatment of HIV Infected Adults in Europe, , http://www.eacsociety.org/files/guidelines_8.2-english.pdf, Version 8.0. Accessed 31 July 2017; Günthard, H.F., Saag, M.S., Benson, C.A., Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel (2016) JAMA, 316, pp. 191-210; (2006) Guidelines for The Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, , https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents. Updated 14 July Accessed 26 April 2017; Armenia, D., Soulie, C., Di Carlo, D., A very low geno2pheno false positive rate is associated with poor VIRO-immunological response in drug-naive patients starting a first-line HAART (2014) PLoS One, 9, p. e105853; Di Biagio, A., Rusconi, S., Marzocchetti, A., The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy (2014) J Med Virol, 86, pp. 1648-1655; Hanf, K.M., Jovelin, T., Hall, N., Impact of baseline viral load, time to viral suppression, and drug class on virologic rebound (2015) 15th European AIDS Conference, , 21–24 October Barcelona, Spain. Abstract PS10/1; Daar, E.S., Tierney, C., Fischl, M.A., Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 (2011) Ann Intern Med, 154, pp. 445-456; Molina, J.M., Clotet, B., Van Lunzen, J., Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, Phase 3b study (2015) Lancet HIV, 2, pp. e127-e136; Smith, K.Y., Patel, P., Fine, D., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/ lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir for initial HIV treatment (2009) AIDS, 23, pp. 1547-1556; Soriano, V., Arastéh, K., Migrone, H., Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial (2011) Antivir Ther, 16, pp. 339-348; Patel, D.A., Snedecor, S.J., Tang, W.Y., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: A systematic review and network meta-analysis (2014) PLoS One, 9, p. e105653; Wang, X., Song, X., Tang, S., Rong, L., Dynamics of an HIV model with multiple infection stages and treatment with different drug classes (2016) Bull Math Biol, 78, pp. 322-349; Riddler, S.A., Haubrich, R., DiRienzo, A.G., Class-sparing regimens for initial treatment of HIV-1 infection (2008) N Engl J Med, 358, pp. 2095-2106; Chéret, A., Nembot, G., Mélard, A., Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): A randomised, open-label, Phase 3 trial (2015) Lancet Infect Dis, 15, pp. 387-396; Markowitz, M., Evering, T.H., Garmon, D., A randomized open-label study of 3- Versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals (2014) J Acquir Immune Defic Syndr, 66, pp. 140-147; Clotet, B., Feinberg, J., Van Lunzen, J., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label Phase 3b study (2014) Lancet, 383, pp. 2222-2231; Kelley, C.F., Kitchen, C.M., Hunt, P.W., Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment (2009) Clin Infect Dis, 48, pp. 787-794; Lok, J.J., Bosch, R.J., Benson, C.A., Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection (2010) AIDS, 24, pp. 1867-1876

PY - 2018

Y1 - 2018

KW - antiretrovirus agent

KW - atazanavir plus ritonavir

KW - darunavir plus ritonavir

KW - dolutegravir

KW - efavirenz

KW - elvitegravir

KW - integrase inhibitor

KW - lopinavir plus ritonavir

KW - nevirapine

KW - nonnucleoside reverse transcriptase inhibitor

KW - proteinase inhibitor

KW - raltegravir

KW - RNA directed DNA polymerase inhibitor

KW - adult

KW - antiretroviral therapy

KW - CD4+ T lymphocyte

KW - clinical practice

KW - Conference Paper

KW - female

KW - human

KW - Human immunodeficiency virus 1 infection

KW - immune reconstitution

KW - major clinical study

KW - male

KW - observational study

KW - prescription

KW - priority journal

KW - probability

KW - retrospective study

KW - survival analysis

KW - virus load

U2 - 10.3851/IMP3197

DO - 10.3851/IMP3197

M3 - Article

VL - 23

SP - 249

EP - 257

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 3

ER -